Sipuleucel-T: When and for Whom to Recommend It.

Related Articles

Sipuleucel-T: When and for Whom to Recommend It.

Oncology (Williston Park). 2017 Dec 15;31(12):

Authors: Slovin SF

Abstract
Multiple immunotherapy platforms have been investigated for prostate cancer, but sipuleucel-T still remains the sole approved autologous cellular immune product that can be used in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. While preliminary data for specific checkpoint inhibitors suggest benefit for some patients, leading to durable responses, it has been clear that sipuleucel-T can affect not only the intratumoral milieu but also systemic immune populations. This means that the immune system can respond to sipuleucel-T in such a way that it may also effect an immunomodulatory response to other current and future treatments. It is clear that sipuleucel-T is here to stay; nevertheless, efforts to enhance its efficacy continue. A challenge that continues to be investigated is the question of how and when to use this immune therapy as part of the current continuum of competing approved agents.

PMID: 29297175 [PubMed - in process]

http://ift.tt/2EVUUyG